Alpha-9 Oncology
PrivateLast Round
Series C
Oct 23, 2024
Total Funding Raised
$261M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Alpha-9 Oncology is a biotechnology company that develops targeted radiopharmaceuticals for the diagnosis and treatment of solid and hematologic malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alpha-9 Oncology Comparables
Compare Alpha-9 Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abdera Therapeutics | 90% | |
| Convergent Therapeutics | 87% | |
| Ratio Therapeutics Inc. | 86% |
Alpha-9 Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 23, 2024 | ||||
| Series B | Dec 14, 2022 | ||||
| Series A | Apr 28, 2021 |
Key People
Founding team and executive leadership
Alpha-9 Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series C |
| Longitude Capital | Series B, Series C, Series A |
| Janus Henderson Group | Series C |
| Aberdeen Group plc | Series C |
| RA Capital Management | Series C |
| Digitalis Ventures | Series C |
| abrdn Inc. | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 16, 2026
Grew 37% QoQ, from 27 to 37 employees.
- Jul 25, 2026
Monthly visitors increased 58% MoM, reaching 2.8K.
Alpha-9 Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alpha-9 Oncology's valuation, stock price, and market status.
Is Alpha-9 Oncology a public or private company?
Alpha-9 Oncology is a private company.
What is the current stock price of Alpha-9 Oncology?
Alpha-9 Oncology is a private company with no public stock price. No recent secondary market data is available.
How much is Alpha-9 Oncology worth (valuation)?
Valuation information for Alpha-9 Oncology is not publicly available.
Can I buy Alpha-9 Oncology stock?
Alpha-9 Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alpha-9 Oncology's last funding round?
Alpha-9 Oncology's most recent funding round was Series C on October 23, 2024.
Who are the main investors in Alpha-9 Oncology?
Key investors in Alpha-9 Oncology include Longitude Capital, Nextech Invest, Lightspeed Venture Partners, Ascenta Capital.
Will Alpha-9 Oncology IPO soon?
No public IPO plans have been announced for Alpha-9 Oncology.
How can I track Alpha-9 Oncology secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alpha-9 Oncology's secondary market activity and sign up for updates.